Annals of Surgical Oncology, Vol 6, Issue 1 46-56, Copyright © 1999 by Society of Surgical Oncology

ARTICLES

Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer

D. H. Roukos
Academic Department of Surgery, Medical School, University of Ioannina, Greece.

BACKGROUND: The treatment strategy for gastric cancer is determined by the stage of disease. Advances in diagnostic techniques such as endoscopic ultrasound (EUS) and in staging have increased the accuracy of pretreatment staging. Correct staging is a prerequisite for the optimal treatment of gastric cancer patients. Long-term expected survival and quality of life (QOL) are the major criteria determining the therapeutic strategy. RESULTS: Surgical resection offers excellent survival rates for early gastric cancer (EGC) patients. D1 resection is sufficient for mucosal cancers (T1m) and for most submucosal cancers (Tlsm); however, for the rest (about 5%) of these patients with N2 disease a D2 resection is required for complete tumor resection (R0). Considering QOL, endoscopic mucosal resection (EMR) or laparoscopic wedge resection is the best front-line therapy for several mucosal cancers. Prediction and selection of node-negative patients with the help of certain macroscopic and histologic criteria can eliminate the possibility for residual disease in perigastric lymph nodes. However, long-term survival data are needed before these new techniques become more generally accepted. In contrast, an aggressive approach is necessary for the treatment of advanced gastric cancer. Total gastrectomy, with the exception of distal tumors that can be treated by subtotal gastrectomy, is the procedure of choice. Splenectomy is indicated for proximal advanced tumors. Distal pancreatectomy should be avoided, however, because its adverse effect has been documented in all randomized trials. Although the survival benefit of extended (D2) lymphadenectomy is unproven in randomized trials, D2 resection increases the R0 resection rate and may improve survival in some selected node-positive patients. D2 resection has little effect on preventing peritoneal tumor spread and liver metastasis, and the traditional late administration of chemotherapeutic drugs has been proven ineffective. Current data suggest a possible beneficial effect of combined treatment for patients with local advanced gastric cancer (LAGC). Ongoing phase-III randomized trials will prove whether patients with LAGC treated by neoadjuvant chemotherapy plus D2 resection versus surgery alone or surgery plus intraoperative intraperitoneal chemotherapy derive any benefit from these combined treatment modalities. CONCLUSION: Evaluation of all information concerning tumor stage, location, histologic type, expected survival, and QOL after resection is of paramount importance for the surgeon planning the extent of surgery. The therapeutic approach should be stratified according to the stage of disease.

This article has been cited by other articles:

				D. Ziogas, E. Ignatiadou, and M. Fatouros Lumpectomy and Partial Breast Irradiation - Risks and Benefits for Early Breast Cancer Ann. Surg. Oncol., August 1, 2008; 15(8): 2352 - 2353. [Full Text] [PDF]

				T. Liakakos Minimal Residual Disease in Breast Cancer: Can It Be Used as a Prognostic Marker? Ann. Surg. Oncol., June 1, 2008; 15(6): 1793 - 1794. [Full Text] [PDF]

				T. Liakakos and E. G. Lykoudis Local Control, Aggressive Surgery, and Overall Survival for Breast Cancer Ann. Surg. Oncol., May 1, 2008; 15(5): 1544 - 1546. [Full Text] [PDF]

				E. Hanisch, D. Ziogas, D. Roukos, and C. Hottenrott Advances in Laparoscopic Gastrectomy Expand Clinical Use Ann. Surg. Oncol., April 1, 2008; 15(4): 1251 - 1252. [Full Text] [PDF]

				H. Harissis and M. Fatouros Nodal Micrometastases Status--Will It Influence Decisions on Surgical and Adjuvant Treatment for Breast Cancer? Ann. Surg. Oncol., April 1, 2008; 15(4): 1256 - 1257. [Full Text] [PDF]

				E. Lykoudis, N. Xeropotamos, D. Ziogas, and M. Fatouros Breast Conservation Therapy: Multiple Reexcisions or Subcutaneous and Nipple-Sparing Mastectomy? Ann. Surg. Oncol., March 1, 2008; 15(3): 943 - 944. [Full Text] [PDF]

				E. Briasoulis, M. Fatouros, and D. H. Roukos Level I Evidence in Support of Perioperative Chemotherapy for Operable Gastric Cancer: Sufficient for Wide Clinical Use? Ann. Surg. Oncol., October 1, 2007; 14(10): 2691 - 2695. [Full Text] [PDF]

				M. Yun, J. S. Lim, S. H. Noh, W. J. Hyung, J. H. Cheong, J. K. Bong, A. Cho, and J. D. Lee Lymph Node Staging of Gastric Cancer Using 18F-FDG PET: A Comparison Study with CT J. Nucl. Med., October 1, 2005; 46(10): 1582 - 1588. [Abstract] [Full Text] [PDF]

				S. Shimoyama, H. Yasuda, K. Mafune, and M. Kaminishi Indications of a Minimized Scope of Lymphadenectomy for Submucosal Gastric Cancer Ann. Surg. Oncol., August 1, 2002; 9(7): 625 - 631. [Abstract] [Full Text] [PDF]

				K. Y. Lee, S. H. Noh, W. J. Hyung, J. H. Lee, K. H. Lah, S. H. Choi, and J. S. Min Impact of Splenectomy for Lymph Node Dissection on Long-Term Surgical Outcome in Gastric Cancer Ann. Surg. Oncol., June 1, 2001; 8(5): 402 - 406. [Abstract] [Full Text] [PDF]